MabSpace Biosciences Co., Ltd, a biotechnology company focused on the discovery and early development of antibody based therapeutics, has signed a collaborative contract of a novel therapeutic antibody with Genor Biopharma Co. Ltd (GenorBio), the mAb division of Walvax Group, one of the leading therapeutic antibody development companies in China.
[adsense:336x280:8701650588]
According to the agreement, MabSpace will be responsible for the discovery and selection of fully human lead antibodies and GenorBio for the further development of the selected candidate molecules.
[adsense:468x15:2204050025]
GenorBio will own exclusive global rights on the resulting therapeutic candidates for the nominated targets, while MabSpace will receive upfront R&D funding, regulatory milestones and royalty on global sales.
Subscribe to PharmaTutor News Alerts by Email >>
